Focus Stocks
Akamai Close to Resistance
Published on Wednesday, 08 February 2012 07:28 Written by TradersHuddle Wire
New York, February 8th (TradersHuddle.com) - Shares of Akamai Technologies, Inc. (NASDAQ:AKAM) are trading very close to calculated resistance at $34.25 with the current price action closing at just $33.65 placing the stock near levels that make it difficult to buy.
Akamai Technologies, Inc. (NASDAQ:AKAM) provides global delivery services for Internet content, streaming media, and applications and global Internet traffic management. The Company uses technology and software to offer tools that provide reporting and management capabilities; network data feeds and Website analytics, which provide customers with real time data about the performance of their content and applications over the Internet.
Akamai's current stock range is defined by current calculated support defined at $31.01 and by the resistance level at $34.25, the stock is clearly over-extended from support, making it difficult to establishing new long positions at this level.
Traders don't have a clear entry point for Akamai, as the stock is well above support, however, as the stock pulls back towards $31.01 it will definitely provide a reference point to establish a trade. On the other hand if the stock decides to break above resistance level at $34.25 then traders will get an opportunity to enter Akamai stock by establishing a position as the stock moves to a higher range.
Related Articles
- Are the Bears Taking Control over Akamai?
- Akamai Broke Support
- Is Akamai Expecting a Break Out?
- Up/Downgrades
- Trading Idea: Is Akamai close to Support?
- Is Akamai Close to Support?
- Trading Idea: Key levels for Akamai
- Akamai Is In OverSold Territory
- Stocks Gained; The Dow Logged Third Straight Win
- NASDAQ 100's Update, In focus: CTXS, XLNX, RIMM, NIHD, AKAM
Related Partner Headlines
- Akamai Technologies Inc. (AKAM): Today's Featured Internet Winner - TheStreet.com
- UPDATE: Canaccord Genuity Lowers Akamai Technologies' PT - Benzinga
- Financial Breakfast: Morning News Summary for May 16, 2012 - Benzinga
- Benzinga's Top Upgrades - Benzinga
- Akamai Technologies Inc. (AKAM): Today's Featured Internet Loser - TheStreet.com
- Akamai Technologies Inc. (AKAM): Today's Featured Internet Loser - TheStreet.com
- Insiders Trading AKAM, CRI, PMTI, MSFT - TheStreet.com
- Akamai up Over 4% After Insider Buying - Benzinga
- Akamai Technologies Inc. (AKAM): Today's Featured Internet Loser - TheStreet.com
- Analysts' Actions: AKAM, HES, GD, MAR - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Coming Week: Top Nine Earnings on Deck - TheStreet.com -
Something's Not Right in the Video-Game Space - TheStreet.com -
For Ambitious Students, Entrepreneurship Can Be a Big Win - TheStreet.com -
Stock Futures Rise on Eurobond Talk - TheStreet.com -
You Can Let Your Guard Down: Ask Noah - TheStreet.com -
Apple Strengthens Its Supply Chain - TheStreet.com -
NYSE Is Winning the IPO Listing War - TheStreet.com -
Toyota Is Back as May Sales Continue Auto Industry Recovery - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis -
SunOpta Enters Into Agreement to Divest Its Canadian Based Natural Health Products Business -
PC Connection, Inc. (PCCC) To Present at The SeeThruEquity First Annual Small Cap Investor Conference on Tuesday, June 5, 2012 -
Aeroflex Announces Amendment to Credit Agreement -
Alliance Data to Participate at Upcoming Investor Conferences -
PCA3 Test Featured at American Urological Association Meeting -
MOCON Announces Quarterly Dividend -
Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus









